Pulmonary radiological-, physiological-, and clinical side-effects after adjuvant radiotherapy in breast cancer
Reviewer: Ryan Smith, MD
Last Modified: May 31, 2003
Presenter: P.A. Lind Presenter's Affiliation: Karolinska Institute, Sweden Type of Session: Poster
Adjuvant radiation therapy used in the treatment of breast cancer has been shown to decrease cancer deaths
However, toxicity from radiation therapy leads to an increase in deaths from other causes
At least some of these increased deaths are thought to be secondary to lung toxicity
This study was done to study the pulmonary side effects of adjuvant radiation therapy in terms of: Radiological changes (as measured on CT scan), Physiological changes (as measured by pulmonary function test parameters), and clinical signs of radiation pneumonitis
Materials and Methods
125 women were studied
All had 3D dose planning of adjuvant radiation therapy, with prospectively gathered data
Chest CT scans were done pre treatment and 4 months post radiation treatment
68 patients had none to slight CT changes and 10 patients had moderate to severe changes noted on CT scans
V20 (volume of lung receiving at least 20 Gy) and older age were predictive of CT changes
V20 was the only predictor of vital capacity change. However, the maximum vital capacity change was 600 cc, with the vast majority less than 400 cc if at all
V20 and pre-radiation chemotherapy were predictive of DLCO changes. Again, these DLCO changes, for the most part, were mild.
96 patients had no symptoms of radiation pneumonitis and 29 patients had mild to moderate radiation pneumonitis changes
V20 and age were predictive of the development of symptoms of radiation pneumonitis
V20 is the best predictor of radiological, physiological, and clinical symptoms of radiation pneumonitis. There was no use for V30.
Older age was an independent predictor of CT changes and the development of radiation pneumonitis
Pre-radiation chemotherapy also influences DLCO changes, perhaps due to chemotherapy's effect on membrane diffusion of alveoli.
This supports the further use of 3-D treatment planning on minimizing the dose to the lung.
As noted above, lung toxicity from adjuvant radiation for breast cancer is a major concern. This study indicated that the most influential predictor on the development of lung toxicity is the amount of lung exposed to at least 20 Gy. This does lend support to the fact that 3-D planning should be used to decrease the amount of lung exposure as much as possible. However, the changes in CT scan have not been proven to be clinically useful and the physiological changes seen were small. In addition, the vast majority of patients developed no clinical symptoms or mild symptoms that presumably dissipated with conservative management. The largest causes of long-term toxicity in relation to the lung receiving radiation is the development of secondary malignancies (lung cancer) and progressive pulmonary toxicity. Although from this data, the development of irreversible lung disease from radiation theapy would be small, it is certainly not zero. Therefore, their baseline conclusion that 3-D planning should be used to spare the lung as much as possible is a logical one supported by their data.
Oncolink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.
Jun 4, 2013 - For women with breast cancer, low-dose weekly paclitaxel is as effective as the standard-dose regimen given every two weeks, with fewer side effects; and axillary radiotherapy may be better than axillary lymph node dissection in the case of positive sentinel lymph node biopsy, according to two studies presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.